Considering the progress of molecular biological technologies, the detection of cell-free fetal DNA (cffDNA) as a noninvasive prenatal testing (NIPT) will play an important role for the screening of different aneuploidies. Comparing with the invasive procedures such as amniocentesis and chorionic villus sampling, associated with a small risk of pregnancy loss, the use of NIPT will open new perspectives, having a reduced risk of complications. The common chromosome aneuploidies detectable are trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Some techniques are available for isolating cffDNA, such as polymerase chain reaction, fetal single nucleotide polymorphism, massively parallel signature sequencing or directed DNA analysis, which selectively sequence relevant chromosomes. Therefore, a noninvasive test like cffDNA should be one of the most significant directions in the future of obstetrics, by reducing the number of invasive procedures and the loss of normal fetuses. [ABSTRACT FROM AUTHOR]